Quotes 5-day view Delayed Nasdaq
01/15/2021
01/19/2021
01/20/2021
01/21/2021
01/22/2021
Date
68.61(c)
69.38(c)
67.71(c)
66.44(c)
69.48(c)
Last
435 476
510 003
627 089
446 035
587 481
Volume
-1.61% +1.12% -2.41% -1.88% +4.58% Change
Sales 2020
22,5 M - -
Net income 2020
-431 M - -
Net Debt 2020
24,8 M - -
P/E ratio 2020
-19,1x
Yield 2020
-
Sales 2021
79,8 M - -
Net income 2021
-443 M - -
Net Debt 2021
135 M - -
P/E ratio 2021
-20,5x
Yield 2021
-
Capitalization
8 516 M 8 516 M -
EV / Sales 2020
379x
EV / Sales 2021
108x
Nbr of Employees
369
Free-Float
56,4%
BridgeBio Pharma, Inc. is discovering and developing medicines that target well-characterized genetic diseases. The Company’s product platform divided into three key categories: Mendelian, Oncology and Gene therapy. The Company’s pipeline programs include product candidates ranging from early discovery to late-stage development. The Company’s products include BBP-265, BBP-831, BBP-631 and BBP-454.
Notations Surperformance© of BridgeBio Pharma, Inc.
Trading Rating : Investor Rating :
All news about BRIDGEBIO PHARMA, INC.
01/20 BRIDGEBIO PHARMA, INC. : Submission of Matters to a Vote of Security Holders, Ot..AQ
01/20 BRIDGEBIO PHARMA : Stockholders of BridgeBio Pharma Inc and Eidos Therapeutics I..AQ
01/19 Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve B.. GL
01/19 miRagen Changes Name to Viridian; Names Jonathan Violin CEO, Barrett Katz Chi.. MT
01/13 BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Announce January 21, 2021.. GL
01/12 BRIDGEBIO PHARMA, INC. : Other Events (form 8-K)AQ
01/07 BRIDGEBIO PHARMA : Director, Strategy & TransactionsPU
01/06 BRIDGEBIO PHARMA : Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4..AQ
01/05 BRIDGEBIO PHARMA : Leading Independent Proxy Advisory Firm ISS Recommends Bridge..AQ
01/04 BRIDGEBIO PHARMA : Principal Accounting Officer Yi Ching Yau Steps DownMT
01/04 BRIDGEBIO PHARMA, INC. : Change in Directors or Principal Officers (form 8-K)AQ
01/04 BRIDGEBIO PHARMA : Gets Proxy Advisory Firm Support For Merger With EidosMT
01/04 Leading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma and E.. GL
2020 BRIDGEBIO PHARMA : UCSF Team Up to Accelerate Development of Therapeutics for Ge..MT
2020 UCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therap.. GL
News in other languages on BRIDGEBIO PHARMA, INC.
- No features available -
Analyst Recommendations on BRIDGEBIO PHARMA, INC.
Chart BRIDGEBIO PHARMA, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends BRIDGEBIO PHARMA, INC.
Short Term Mid-Term Long Term Trends Neutral Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
8
Average target price
66,63 $
Last Close Price
69,48 $
Spread / Highest target
31,0%
Spread / Average Target
-4,11%
Spread / Lowest Target
-32,4%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
